Hilton Hotels Corporation Common Stock vs TransMedics Group Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $328 (market cap $73.63B), while TransMedics Group Inc trades at $73.86 (market cap $2.54B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 29× TransMedics Group Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| HLT | TMDX | |
|---|---|---|
Market Cap | $73.63B | $2.54B |
Sector | Consumer Cyclical | Technology |
52-Week High | $350.22 | $150.42 |
52-Week Low | $256.75 | $61.99 |
Enterprise Value | $86.12B | $2.94B |
Dividend Yield | 0.19% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →